Article

Pharmacy Tied to Meningitis Outbreak Files for Bankruptcy

The New England Compounding Center, the compounding pharmacy that produced the tainted drugs that killed 39 people and injured more than 600 others, filed for bankruptcy Friday.

The Framingham, Mass., company shut its doors in October after public health officials traced a nationwide outbreak of meningitis to the firm's shipments of tainted vials of methylprednisolone acetate, an injectable drug prescribed by some pain physicians for back ailments.

Read the full story: http://bit.ly/Tjweno

Source: ModernHealthcare.com

Related Videos
Julia Logan
Dr Luis Carvajal-Carmona
Dr Ravindra Uppalurdi
Dr Ravindra Uppalurdi
Andrew Kuykendall, MD, Moffitt Cancer Center
John Michael O'Brien, PharmD, MPH
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Related Content
AACR Panelists Call on Scientists to Stand Up Against Cuts That Threaten Progress, Patients, and Future Discoveries
April 27th 2025

AACR Panelists Call on Scientists to Stand Up Against Cuts That Threaten Progress, Patients, and Future Discoveries

Mary Caffrey
The session follows the American Association for Cancer Research's (AACR) prior call to action against executive orders that would harm the National Institutes of Health.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
female infertility | Image Credit: © dizain-stock.adobe.com
April 27th 2025

No Definitive Link Found Between Female Infertility and Gynecological Cancer

Maggie L. Shaw
New research explores the complex relationship between female infertility and gynecological cancers, revealing minimal links and emphasizing the need for further studies.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
April 25th 2025

Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

Rose McNulty
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Elderly woman holding her hands | Image credit: Evrymmnt - stock.adobe.com
April 25th 2025

Clinical, Real-World Data Support Importance of Tocilizumab for RA

AJMC Contributor
Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular benefits in recent studies.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo